NCT06479239View on ClinicalTrials.gov

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2031

Conditions
Pancreas CancerPancreatic Cancer
Interventions
DRUG

EGFR FPBMC

Participants will receive 8 weekly infusions of EGFR FPBMC, then 8 additional infusions every 2 weeks.

Trial Locations (1)

22903

RECRUITING

University of Virginia, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER